BR112013011441B8 - Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto - Google Patents

Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto

Info

Publication number
BR112013011441B8
BR112013011441B8 BR112013011441A BR112013011441A BR112013011441B8 BR 112013011441 B8 BR112013011441 B8 BR 112013011441B8 BR 112013011441 A BR112013011441 A BR 112013011441A BR 112013011441 A BR112013011441 A BR 112013011441A BR 112013011441 B8 BR112013011441 B8 BR 112013011441B8
Authority
BR
Brazil
Prior art keywords
compounds
compound
pharmaceutical composition
glycosidase inhibitors
inhibitors compounds
Prior art date
Application number
BR112013011441A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013011441B1 (pt
BR112013011441A2 (pt
Inventor
Liu Kun
G Selnick Harold
Chang Jiang
J Mceachern Ernest
Mu Changwei
Shi Feng
J Vocadlo David
Wang Yaode
Wei Zhongyong
Zhou Yuanxi
Zhu Yongbao
Original Assignee
Alectos Therapeutics Inc
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/078528 external-priority patent/WO2012061972A1/en
Application filed by Alectos Therapeutics Inc, Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Alectos Therapeutics Inc
Publication of BR112013011441A2 publication Critical patent/BR112013011441A2/pt
Publication of BR112013011441B1 publication Critical patent/BR112013011441B1/pt
Publication of BR112013011441B8 publication Critical patent/BR112013011441B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
BR112013011441A 2010-11-08 2011-11-08 Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto BR112013011441B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/CN2010/078528 WO2012061972A1 (en) 2010-11-08 2010-11-08 Selective glycosidase inhibitors and uses thereof
CNPCT/CN2010/078528 2010-11-08
US41859610P 2010-12-01 2010-12-01
US61/418596 2010-12-01
PCT/CN2011/080691 WO2012062157A1 (en) 2010-11-08 2011-10-12 Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors
CNPCT/CN2011/080691 2011-10-12
PCT/US2011/059668 WO2012064680A1 (en) 2010-11-08 2011-11-08 Selective glycosidase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
BR112013011441A2 BR112013011441A2 (pt) 2016-07-19
BR112013011441B1 BR112013011441B1 (pt) 2021-11-09
BR112013011441B8 true BR112013011441B8 (pt) 2023-04-18

Family

ID=46051261

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011441A BR112013011441B8 (pt) 2010-11-08 2011-11-08 Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto

Country Status (12)

Country Link
EP (1) EP2637503B1 (https=)
JP (1) JP5965407B2 (https=)
KR (1) KR101922266B1 (https=)
AR (1) AR083798A1 (https=)
AU (2) AU2011326186A1 (https=)
BR (1) BR112013011441B8 (https=)
CA (1) CA2816798C (https=)
ES (1) ES2600028T3 (https=)
MX (1) MX336611B (https=)
RU (1) RU2592285C2 (https=)
TW (1) TW201249848A (https=)
WO (1) WO2012064680A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
RU2609210C2 (ru) * 2010-12-23 2017-01-31 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
EP2688899B1 (en) 2011-03-24 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726468B1 (en) 2011-06-27 2017-04-12 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
BR112013033098B8 (pt) 2011-06-27 2021-03-23 Alectos Therapeutics Inc inibidores de glicosidade seletivos e usos dos mesmos
EP2847199B1 (en) * 2012-05-08 2017-10-25 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890676B1 (en) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
KR20150079711A (ko) * 2012-10-31 2015-07-08 알렉토스 테라퓨틱스 인크. 글리코시다아제 저해제 및 이의 용도
WO2014100934A1 (en) * 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
RU2748383C1 (ru) * 2020-10-21 2021-05-25 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Способ терапии болезни Тея-Сакса и болезни Сандхоффа с помощью генетически модифицированных мезенхимных стволовых клеток человека со сверхэкспрессией β-гексозаминидазы A
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1441749A1 (ru) * 1987-03-16 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ
CA2599843C (en) 2005-03-01 2013-08-27 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AU2007291870B2 (en) * 2006-08-31 2012-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
CA2732335A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CA2737267A1 (en) 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
ES2568603T3 (es) * 2011-08-25 2016-05-03 Merck Patent Gmbh Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasas

Also Published As

Publication number Publication date
RU2013126531A (ru) 2014-12-20
MX336611B (es) 2016-01-22
JP2013541596A (ja) 2013-11-14
TW201249848A (en) 2012-12-16
AU2011326186A8 (en) 2013-08-01
ES2600028T3 (es) 2017-02-06
BR112013011441B1 (pt) 2021-11-09
EP2637503B1 (en) 2016-09-14
CA2816798A1 (en) 2012-05-18
CA2816798C (en) 2019-02-26
AU2011326186A1 (en) 2013-05-23
KR20130129974A (ko) 2013-11-29
JP5965407B2 (ja) 2016-08-03
EP2637503A1 (en) 2013-09-18
BR112013011441A2 (pt) 2016-07-19
RU2592285C2 (ru) 2016-07-20
MX2013005118A (es) 2013-07-29
WO2012064680A1 (en) 2012-05-18
AU2016202186A1 (en) 2016-04-28
EP2637503A4 (en) 2014-04-09
AU2016202186B2 (en) 2017-10-12
AR083798A1 (es) 2013-03-20
KR101922266B1 (ko) 2018-11-26

Similar Documents

Publication Publication Date Title
BR112013011441B8 (pt) Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto
BR112013033098B8 (pt) inibidores de glicosidade seletivos e usos dos mesmos
BR112015009638A2 (pt) inibidores de glicosidase e usos dos mesmos
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
MY165728A (en) Selective glycosidase inhibitors and uses thereof
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
HN2009001112A (es) Inhibidores de la actividad de la akt
BRPI0914599A2 (pt) métodos para tratar ou prevenir câncer, para inibir uma pim quinase, e para fabricar um composto, composto, composição farmacêutico, e, uso de um composto
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0610322B8 (pt) inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
BR112014003681A2 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112012007241A2 (pt) compostos , composição farmacêutica, método para tratar desordens, uso dos compostos, medicamento, método para selecionar inibidores com pequenas moléculas de pcsk9 e pequenas moléculas
BR112012007828A2 (pt) compostos, processo para preparar os compostos, e, composição farmacêutica.
BR112013003358A2 (pt) heteroaris e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: ALECTOS THERAPEUTICS INC. (CA) ; MERCK SHARP AND DOHME LLC (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.